Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Exclusion of Major Adverse Cardiac Events in Emergency Department Chest Pain Patients: A Prospective Observational Study.

The Journal of emergency medicine·2017
Same author

Aggregation-induced emissive nanoparticles for fluorescence signaling in a low cost paper-based immunoassay.

Colloids and surfaces. B, Biointerfaces·2016
Same author

Age-specific non-invasive transcutaneous Doppler ultrasound derived haemodynamic reference ranges in elderly Chinese adults.

BBA clinical·2015
Same author

Evaluation of the Recognition of Stroke in the Emergency Room (ROSIER) scale in Chinese patients in Hong Kong.

PloS one·2014
Same author

Validating a pragmatic definition of shock in adult patients presenting to the ED.

The American journal of emergency medicine·2014
Same author

Influence of different positions on hemodynamics derived from noninvasive transcutaneous Doppler ultrasound.

Physiological reports·2013

Related Experiment Video

Updated: Jul 11, 2026

Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting
08:05

Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting

Published on: December 12, 2011

New trends in immunoassays.

Cangel Pui-yee Chan1, Yiu-chi Cheung, Reinhard Renneberg

  • 1Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, SAR Hong Kong, China. cangel@ust.hk

Advances in Biochemical Engineering/Biotechnology
|September 18, 2007
PubMed
Summary

Novel signal amplification technologies, including nanocrystals and aggregation-induced emission (AIE), enhance immunoassay sensitivity. Innovations in lateral-flow assays are driving rapid, point-of-care diagnostics for better patient care.

More Related Videos

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Fabricating a UV-Vis and Raman Spectroscopy Immunoassay Platform
09:02

Fabricating a UV-Vis and Raman Spectroscopy Immunoassay Platform

Published on: November 10, 2016

Related Experiment Videos

Last Updated: Jul 11, 2026

Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting
08:05

Multiplexed Fluorometric ImmunoAssay Testing Methodology and Troubleshooting

Published on: December 12, 2011

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Fabricating a UV-Vis and Raman Spectroscopy Immunoassay Platform
09:02

Fabricating a UV-Vis and Raman Spectroscopy Immunoassay Platform

Published on: November 10, 2016

Area of Science:

  • Biotechnology
  • Analytical Chemistry
  • Medical Diagnostics

Background:

  • Immunoassays are crucial for disease diagnosis, with growing demand for rapid, point-of-care (POC) testing due to chronic diseases and infectious outbreaks.
  • Traditional immunoassays face limitations in sensitivity and speed, necessitating advanced technologies for improved diagnostic capabilities.
  • The development of novel signal amplification strategies and next-generation lateral-flow assays is key to addressing these challenges.

Purpose of the Study:

  • To explore innovative signal amplification technologies for immunoassays, focusing on enhancing sensitivity and detection limits.
  • To review advancements in lateral-flow assay (LFA) technology, particularly those enabling point-of-care (POC) applications.
  • To highlight how these technological improvements facilitate more efficient diagnosis and patient management.

Main Methods:

  • Investigated novel signal amplification techniques, such as biofunctional nanocrystals (releasable fluorophores) and aggregation-induced emission (AIE).
  • Examined bio-barcode assays utilizing magnetic beads and gold nanoparticle probes for analyte concentration and signal amplification.
  • Reviewed new lateral-flow assay formats, including digital-style and immuno-threshold-based assays, and molecular compact discs for multiplexed detection.

Main Results:

  • New amplification methods like AIE and nanocrystals significantly improve immunoassay sensitivity and lower detection limits.
  • Bio-barcode assays demonstrate effective signal amplification through analyte concentration and oligonucleotide labeling.
  • Advanced LFAs offer semi-quantitative or quantitative results at the point-of-care, simplifying interpretation and improving diagnostic efficiency.

Conclusions:

  • Innovative signal amplification and lateral-flow assay technologies are revolutionizing immunoassays, enabling faster and more sensitive diagnostics.
  • These advancements are crucial for the expansion of rapid, decentralized testing, particularly for managing chronic and infectious diseases.
  • Future developments promise to bring diagnostic capabilities even closer to the patient, enhancing healthcare quality and enabling timely disease monitoring.